News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Almac Discovery Announces Selection of Preclinical Development Candidate for Its Allosteric Akt Inhibitor Programme.


12/17/2012 9:37:27 AM

CRAIGAVON, Northern Ireland--(BUSINESS WIRE)--Almac Discovery is pleased to announce the selection of a preclinical development candidate from its allosteric Akt inhibitor programme. Akt is a key component of the PI3K pathway, one of the major pathways driving tumour growth in many cancer types. ALM301 is a potent, subtype selective Akt1 & Akt2 inhibitor with good pharmacokinetic properties in multiple species, and an excellent selectivity profile over other targets.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES